Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome

European Journal of Haematology

Volumn 89, Issue 6, 2012, Pages 469-477

  Yang, Yujuan ^a   Zhang, Qingxia ^a   Xu, Feng ^a   Chang, Chunkang ^a   Li, Xiao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

5 aza 2 deoxycytidine; Dab2; Methylation; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; DISABLED 2; HEMOGLOBIN; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE; DNA METHYLATION; DOWN-REGULATION; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 84869884659     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12014     Document Type: Article

References (47)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111:4841-51.
2. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-30.
3. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 2010;6:445-55.
4. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
5. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27-56.
6. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-25.
7. Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX. Structure, sequence, and promoter analysis of human Disabled-2 gene (DAB2). Genomics 2000;70:381-6.
8. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998;16:2381-7.
9. Xu XX, Yi T, Tang B, Lambeth JD. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998;16:1561-9.
10. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001;20:2789-801.
11. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 2003;278:6936-41.
12. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH. Regulation of the Wnt signaling pathway by Disabled-2 (Dab2). EMBO J 2003;22:3084-94.
13. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 1998;139:3542-53.
14. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 2007;13:4400-6.
15. Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, Mok SC, Singletary SE, Hung MC. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene 2001;20:6960-4.
16. Anupam K, Tusharkant C, Gupta SD, Ranju R. Loss of Disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 2006;12:6041-5.
17. Huang Y, Friess H, Kleeff J, Esposito I, Zhu Z, Liu S, Mok SC, Zimmermann A, Büchler MW. Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis. Lab Invest 2001;81:863-73.
18. Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H, Buchler MW. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 2002;45:1242-8.
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
21. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 2005.
22. Bagadi SA, Prasad CP, Srivastava A, Prashad R, Gupta SD, Ralhan R. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Trea 2007;104:277-86.
23. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52:247-52.
24. Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104-13.
25. Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000;19:4847-54.
26. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
27. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82.
28. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006;103:1412-7.
29. Pomraning KR, Smith KM, Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 2009;47:142-50.
30. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2(Suppl. 1):S4-11.
31. Cheung HH, Lee TL, Rennert OM, Chan WY. DNA methylation of cancer genome. Birth Defects Res C Embryo Today 2009;87:335-50.
32. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011;117:677-87.
33. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605-13.
34. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-58.
35. Greenberg PL. Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol 2011;34:215-22.
36. Tong JH, Ng DC, Chau SL, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010;10:253-64.
37. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998;17:419-24.
38. Zhou J, Hernandez G, Tu SW, Scholes J, Chen H, Tseng CP, Hsieh JT. Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. Cancer Res 2005;65:6089-96.
39. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
40. Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-96.
41. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 2010;10:9-22.
42. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-702.
43. Keating GM. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2009;69:2501-18.
44. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64.
45. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803.
46. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8.
47. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109:265-73.